Drug intelligence / Profile preview

naporafenib + trametinib

Development stage: Unknown
Lead developer: Erasca
Modality: Small Molecules
Administration: Oral

Overview

Naporafenib + trametinib is an investigational combination therapy targeting the MAPK pathway in cancer. Naporafenib is a pan-RAF inhibitor that blocks the RAF (Rapidly Accelerated Fibrosarcoma) pathway, while trametinib is an FDA-approved MEK inhibitor. This combination has shown promising antitumor activity in NRAS-mutant melanoma and is being evaluated in Phase 3 clinical trials.

Brand names: naporafenib + MEKINIST
Other names: naporafenib + Mekinist

Targets

ARAF (Proto-oncogene serine/threonine-protein kinase A-Raf)BRAF (B-Raf proto-oncogene, serine/threonine kinase)MEK1 (Dual specificity mitogen-activated protein kinase kinase 1)RAF1 (c-Raf-1 (Y340D/Y341D))MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)

Beyond the preview

Go deeper on naporafenib + trametinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on naporafenib + trametinib.

Explore the full profile